2021-10-14 12:52:40 MOTN Motion Acquisition
DocGo
10/14/21 10/1412:52 10/14/2112:52 | Motion Acquisition announces effectiveness of registration statementMotion Acquisition Corp. announced that its registration statement on Form S-4 in connection with its previously announced proposed business combination with Ambulnz, Inc., dba DocGo, a provider of last-mile telehealth and integrated medical mobility services, has been declared effective by the U.S. Securities and Exchange Commission. Motion also announced today that its Annual Meeting of Stockholders to consider and vote upon the Business Combination and related matters has been set for November 2, 2021 at 10:00 a.m. EST. The closing of the Business Combination is subject to approval by Motion's stockholders, and the satisfaction of other customary closing conditions. Motion Acquisition
DocGo
|
|
---|
Hot Stocks
|
FDA approves Novartis' Kymriah CAR-T cell therapy for r/r follicular lymphoma »
13:23 05/28/22 05/2813:23 05/28/2213:23
NVS
Novartis
Novartis announced the US… Novartis announced the US Food and Drug Administration has granted accelerated approval for Kymriah for the treatment of adult patients with relapsed or refractory, or r/r, follicular lymphoma, or FL, after two or more lines of systemic therapy. In accordance with the Accelerated Approval Program, continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). The approval is based on data from the Phase II ELARA trial, a single-arm, open-label trial, in which 90 patients were evaluated for efficacy with a median follow-up of approximately 17 months. Eighty-six percent of patients treated with Kymriah achieved a response including 68% who experienced a complete response, the company noted. "Kymriah is now FDA approved in three indications and remains the only CAR-T cell therapy approved in both adult and pediatric settings," the company stated. ShowHide Related Items >><<
|
Hot Stocks
|
Bristol-Myers announces FDA approves two Opdivo-based regimens »
13:21 05/28/22 05/2813:21 05/28/2213:21
BMY
Bristol-Myers
Bristol Myers Squibb… Bristol Myers Squibb announced that the U.S. Food and Drug Administration has approved both Opdivo in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo plus Yervoy as a first-line treatment for adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, or ESCC, regardless of PD-L1 status. The approvals are based on the Phase 3 CheckMate -648 trial, which evaluated Opdivo in combination with chemotherapy and Opdivo plus Yervoy, each compared to chemotherapy alone, and was the largest Phase 3 trial of an immunotherapy in first-line ESCC, the company stated. Adam Lenkowsky, senior vice president and general manager, U.S., Cardiovascular, Immunology, Oncology, Bristol Myers Squibb, added, "Today's approvals bring two first-line immunotherapy-based treatment options at once, Opdivo in combination with chemotherapy and Opdivo plus Yervoy as the first dual immunotherapy option, to newly diagnosed patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, further building on the role of Opdivo-based regimens in upper gastroesophageal cancers." ShowHide Related Items >><<
|
Periodicals
|
Boeing hasn't delivered on jets or other recovery requisites, Barron's says »
10:41 05/28/22 05/2810:41 05/28/2210:41
BA
Boeing
Boeing's badly… Boeing's badly beaten-up stock might be nearly as weak as it will get, and the big drop seems to have attracted some interest in the shares recently, Al Root writes in this week's edition of Barron's. At this point, Boeing's task is simple-it needs to stop the bleeding. For that to happen, the company needs to deliver more 737 MAX jets to customers and win permission to resume deliveries of the 787 twin-aisle jet. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Under Armour transformation will take much longer to play out, Barron's says »
10:39 05/28/22 05/2810:39 05/28/2210:39
UA
Under Armour
Under Armour
There were a lot of… There were a lot of reasons to be optimistic about Under Armour in April but then May happened, with much of the decline in the stock due to its own missteps, Teresa Rivas writes in this week's edition of Barron's. The company delivered a surprise loss at the start of the month, hurt by supply-chain woes and pandemic-related lockdowns in China. Then last week, it announced the departure of CEO Patrik Frisk, who had led the company's turnaround efforts over the past two years, the author notes. While Under Armour's transformation might not be out of the question, it inevitably looks as if that will now take much longer to play out than Rivas originally thought, at a time when the market has little in the way of patience for retailers that miss the mark. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Snowflake stock finally looks attractive, Barron's says »
10:34 05/28/22 05/2810:34 05/28/2210:34
SNOW
Snowflake
It's been more than… It's been more than 600 days since Snowflake came public in one of the hottest initial public offerings of the pandemic era. It turned out to be a winding, nearly two-year road back to the starting line, Eric J. Savitz writes in this week's edition of Barron's. For investors, there's now an opportunity to make a sharply discounted bet on what remains one of the most impressive growth stories in software, he adds. Snowflake shares peaked at just over $400 last November, but it has been all downhill from there. The stock has swooned 70% over the last six months. This past week, shares briefly traded below their $120 IPO price for the first time ever, the publication notes. While still not a value play, Snowflake now trades at a much more reasonable 13 times expected fiscal 2024 revenue of $3 billion - with a growth rate unmatched in software. The outlook remains strong, and the stock has been de-risked, Savitz writes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Chewy earnings might not be so great but stock could take off, Barron's says »
10:30 05/28/22 05/2810:30 05/28/2210:30
CHWY
Chewy
Chewy is set to report… Chewy is set to report earnings this coming Wednesday. It's expected to report a loss of 10 cents a share on sales of $2.41 billion, and a profit on adjusted earnings before interest, taxes, amortization, and depreciation-or Ebitda-of $6 million. That could be optimistic, Ben Levisohn writes in this week's edition of Barron's. Regardless, Chewy is hoping that it will ultimately have added more subscribers than it lost, the author notes. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Buy Bristol-Myers, rally just getting started, Barron's says »
10:27 05/28/22 05/2810:27 05/28/2210:27
BMY
Bristol-Myers
Bristol-Myers Squibb has… Bristol-Myers Squibb has been a bright spot in a very tough market-and the stock's move higher may just be getting started, Jacob Sonenshine writes in this week's edition of Barron's. While the Revlimid patent concerns haven't gone away, the company now seems better prepared to weather the transition, the author notes. While the stock has gained this year, its shares still look cheap, he adds, arguing that after years of waiting, Bristol appears poised to be a winner once again. Reference Link ShowHide Related Items >><<
|
Periodicals
|
Alphabet, Meta among bargain stocks to buy now, Barron's says »
10:15 05/28/22 05/2810:15 05/28/2210:15
GOOGL
Alphabet Class A
Alphabet
Lam Research
Meta Platforms
Micron
Netflix
Teradyne
With about two-thirds of… With about two-thirds of the stocks in the S&P 500 down more than 20% from their all-time highs and the index itself down 15%, many stocks are on sale, Al Root writes in this week's edition of Barron's. But the stock market isn't like a clothing store, where bargains are happily scooped up, even if not all of them will look as good when you get home. Instead, when stocks are falling, many investors find it difficult to pull the trigger, fearful they'll pick a dud that only adds to the pain that's already afflicting their portfolios. But there are opportunities amid the rubble, the author notes. Among those who fit the bill, Root says, are Alphabet (GOOGL), Lam Research (LRCX), Meta Platforms (FB), Micron (MU), Netflix (NFLX), and Teradyne (TER). Reference Link ShowHide Related Items >><<
|
Conference/Events
|
1-800-Flowers.com management to meet virtually with Oppenheimer »
04:55 05/28/22 05/2804:55 05/28/2204:55
FLWS
1-800-Flowers.com
Virtual Meeting to be… Virtual Meeting to be held on May 28 hosted by Oppenheimer. ShowHide Related Items >><<
|
Conference/Events
|
Integra LifeSciences management to meet virtually with Oppenheimer »
04:55 05/28/22 05/2804:55 05/28/2204:55
IART
Integra LifeSciences
Virtual Meeting to be… Virtual Meeting to be held on May 28 hosted by Oppenheimer. ShowHide Related Items >><<
|
General news
| Treasury Market Summary:… Treasury Market Summary: Risk appetite continued to surge with strong gains across the board on the session, and helping drive the major indexes sharply higher on the week. Trading was on the lighter side, however, ahead of the long Memorial Day weekend. Worries that an aggressive FOMC policy posture with officials intent on destroying growth to curb inflation have been dissipating. Fedspeak, beginning with Chair Powell, has confirmed that a 75 bp hike is not on the table for now, has helped stabilize investor sentiment and encourage bargain hunters. The drop in yields on the month has supported too. The NASDAQ ended the day with a 3.3% pop, with the S&P 500 up 2.47%, while the Dow rallied 1.76%. The Dow snapped an 8-week losing streak, with the S&P 500 and NASDAQ recovered from 7 straight weeks of losses. For the week, the indexes were over 6% firmer. the week's gain to 6.84%. Treasuries were mixed after an abbreviated session with the front end underperforming slightly. The 2-year rose 1.2 bps to 2.475%, while the 10-year closed 1 bp richer at 2.738%. The dollar index finished at 101.63, recovering from an overnight drop to 101.43, but down from the intraday high of 101.93. Data included weaker than expected consumer sentiment, a solid gain in consumer spending, a slowing in y/y PCE prices, and a narrowing in the goods trade deficit. ShowHide Related Items >><<
|
Syndicate
|
SuperCom files to sell 5.65M ordinary shares for holders
17:39 05/27/22 05/2717:39 05/27/2217:39
SPCB
SuperCom
ShowHide Related Items >><<
|
Syndicate
|
Olympic Steel files $200M mixed securities shelf
17:38 05/27/22 05/2717:38 05/27/2217:38
ZEUS
Olympic Steel
ShowHide Related Items >><<
|
Syndicate
|
Rain Therapeutics files automatic mixed securities shelf
17:37 05/27/22 05/2717:37 05/27/2217:37
RAIN
Rain Therapeutics
ShowHide Related Items >><<
|
Hot Stocks
| Akerna announced that the… Akerna announced that the company is implementing a plan to reduce its workforce and operating costs in order to focus its resources, accelerate its path to profitability, and create stakeholder value. The company anticipates reporting $690,000 in total costs in its second quarter to implement the reduction in force, including the following cost elements: $630,000 in severance and associated payroll taxes; $40,000 in legal costs; and $20,000 in employee insurance benefits. Of the total cost, $440,000 in salaries, payroll taxes and benefits costs would have been reported in its second quarter if the reduction in force had not been implemented. "Our sales performance in 2022 has thus far met our expectations. We believe we are showing signs of progress with revenue now at a run rate of $27m at last filing," commented Jessica Billingsley, Akerna's Chief Executive Officer. "While we believe we can continue to grow revenue and continue to reduce expenses over time, we have made the decision to focus our initiatives on our enterprise business and new market expansion of our SMB business, at least until the market conditions and the regulatory environment are in more favorable territory. We can see a path to positive cash flows and profitability, and the board and the management team are committed to getting there on an accelerated timetable. While we continue to deal with liquidity concerns, our headcount reduction and additional cost savings measures represent a material annual cost savings. As part of this restructure, executive leadership team has also collectively agreed to a 25% reduction in salary to help support the company's cost savings initiatives. As we noted on our last earnings call, bookings have been strong and our CARR is $21.1 million, and we are looking to continue to grow our top-line through a combination of enterprise wins as well as the opportunity we see in new market expansion from the SMB side of the business," added Ms. Billingsley. ShowHide Related Items >><<
|
Hot Stocks
|
Northrop Grumman awarded $254.42M Navy contract modification »
17:21 05/27/22 05/2717:21 05/27/2217:21
NOC
Northrop Grumman
Northrop Grumman was… Northrop Grumman was awarded a $254.42M firm-fixed-price modification to a previously awarded contract to exercise an option for production of Surface Electronic Warfare Improvement Program Block 3 Hemisphere systems. Work is expected to be completed by September 2025. FY22 other procurement funds in the amount of $152.65M and FY22 shipbuilding and conversion funds in the amount of $101.77M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting authority. ShowHide Related Items >><<
|
Hot Stocks
|
Raytheon Technologies awarded $624.6M Army contract modification »
17:17 05/27/22 05/2717:17 05/27/2217:17
RTX
Raytheon Technologies
Raytheon was awarded a… Raytheon was awarded a $624.6M modification to contract for the procurement of Stinger missiles and associated equipment. Work locations and funding will be determined with each order, with an estimated completion date of June 30, 2026. U.S. Army Contracting Command is the contracting activity. ShowHide Related Items >><<
|
Syndicate
|
Entera Bio files to sell 3.76M ordinary shares for holders
17:13 05/27/22 05/2717:13 05/27/2217:13
ENTX
Entera Bio
ShowHide Related Items >><<
|
Syndicate
|
Entera Bio files $100M mixed securities shelf
17:10 05/27/22 05/2717:10 05/27/2217:10
ENTX
Entera Bio
ShowHide Related Items >><<
|
Hot Stocks
|
Range Resources CFO sells $1.8M in common stock »
17:08 05/27/22 05/2717:08 05/27/2217:08
RRC
Range Resources
In a regulatory filing,… In a regulatory filing, Range Resources disclosed that its CFO Mark Scucchi sold 55K shares of common stock on May 25th in a total transaction of $1.8M. ShowHide Related Items >><<
|
Syndicate
|
Immix Biopharma files to sell 1.68M shares of common stock »
17:03 05/27/22 05/2717:03 05/27/2217:03
IMMX
Immix Biopharma
ThinkEquity acted as sole… ThinkEquity acted as sole book running manager for the offering. ShowHide Related Items >><<
|
On The Fly
|
What You Missed On Wall Street On Friday »
16:39 05/27/22 05/2716:39 05/27/2216:39
GPS
Gap
Workday
Ulta Beauty
Dell Technologies
Costco
Boot Barn
Zscaler
Marvell
Big Lots
Siga Technologies
Macy's
iQIYI
UnitedHealth
Canopy Growth
Reckitt Benckiser
Navient
SoFi Technologies
Nelnet
Sallie Mae
Didi
Tesla
Farfetch
PMV Pharmaceuticals
Iovance Biotherapeutics
Mirati Therapeutics
Wendy's
Hibbett
Get caught up quickly on… ShowHide Related Items >><<
|
Syndicate
|
Metalla Royalty & Streaming announces updated at-the-market program for $50M »
16:37 05/27/22 05/2716:37 05/27/2216:37
MTA
Metalla Royalty & Streaming
Metalla Royalty &… Metalla Royalty & Streaming is pleased to announce that it has entered into a new equity distribution agreement with a syndicate of agents including BMO Nesbitt Burns Inc., PI Financial Corp., and Scotia Capital Inc., as the Canadian agents, and BMO Capital Markets Corp. and Scotia Capital Inc., as the United States agents, for a new at-the-market equity program. The Distribution Agreement will allow the Company to distribute up to $50 million of common shares of the Company under the 2022 ATM Program. The Offered Shares will be issued by the Company to the public from time to time, through the Agents, at the Company's discretion. The Offered Shares sold under the 2022 ATM Program, if any, will be sold at the prevailing market price at the time of sale. ShowHide Related Items >><<
|
Initiation
|
BNP Paribas initiated with Not Rated at Goldman Sachs »
16:37 05/27/22 05/2716:37 05/27/2216:37
BNPQY
BNP Paribas
Goldman Sachs analyst… Goldman Sachs analyst Chris Hallam initiated coverage of BNP Paribas with Not Rated. ShowHide Related Items >><<
|
Initiation
|
Societe Generale initiated with a Neutral at Goldman Sachs »
16:36 05/27/22 05/2716:36 05/27/2216:36
SCGLY
Societe Generale
Goldman Sachs analyst… Goldman Sachs analyst Chris Hallam initiated coverage of Societe Generale with a Neutral rating and EUR 35 price target. The analyst believes the company "should see growth supported in the coming years by higher interest rates in the traditional banking business and elevated activity levels in Global Markets," however he adds that the company is "not as geared to rates as peers, consensus estimates already imply Global Markets revenue targets will be exceeded and Boursorama's success will make a relatively small impact at a group level over 2023/24." ShowHide Related Items >><<
|